p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682)

Urology

Volumn 71, Issue 5, 2008, Pages 933-937

  D'Amico, Anthony V ^a   Halabi, Susan ^b   Vollmer, Robin ^b   Loffredo, Marian ^a   McMahon, Elizabeth ^a   Sanford, Ben ^b   Archer, Laura ^b   Vogelzang, Nicholas J ^c   Small, Eric J ^d   Kantoff, Philip W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ANDROGEN SUPPRESSION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42749085631     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.005     Document Type: Article

References (26)

1. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation therapy Oncology Group (RTOG) 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
2. Grignon D.J., Caplan R., Sarkar F.H., et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 89 (1997) 158-165
3. Beahrs O.H., Henson D.E., Hutter R.V.P., et al., American Joint Committee on Cancer Staging Manual (1992), Lippincott, Philadelphia 181-186
4. D'Amico A.V., Halabi S., Tempany C., et al. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and recurrence in men managed using radiation therapy: a prospective phase II Cancer and Leukemia Group B Study. Int J Radiat Oncol Biol Phys (2007) (in press)
5. Stapleton A.M.F., Zbell P., Kattan M.W., et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate cancer recurrence after surgery. Cancer 82 (1998) 168-175
6. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
7. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
8. Klein J.P., and Moeschberger M.L. Semiparametric proportional hazards regression with fixed covariates. In: Klein J.P., and Moeschberger M.L. (Eds). Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. (2003), Springer, New York 243-293
9. In: Agresti A. (Ed). An Introduction to Categorical Data Analysis. 2nd ed. (2002), John Wiley & Sons, New York 16-52
10. Ritter M.A., Gilchrist K.W., Voytovich M., et al. The role of p53 in radiation therapy outcomes for favorable- to intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 574-580
11. Rakozy C., Grignon D.J., Li Y., et al. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. Pathol Res Pract 195 (1999) 129-135
12. Che M., Desilvio M., Pollack A., et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys 69 (2007) 1117-1123 Epub ahead of print August 8
13. Rhodes D.R., Sanda M.G., Otte A.P., et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95 (2003) 661-668
14. Petraki C.D., and Sfikas C.P. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 22 (2007) 107-118
15. Tsai M.H., Cook J.A., Chandramouli G.V., et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 67 (2007) 3845-3852
16. Zhang J., and Chen X. The p53 family: prospect for cancer gene therapy. Cancer Biol Ther 11 (2006) 1502-1510
17. Marignol L., Coffey M., Hollywood D., et al. Radiation to control transgene expression in tumors. Cancer Biol Ther 6 (2007) Epub ahead of print May 23
18. Beraza N., and Trautwein C. Restoration of p53 function: a new therapeutic strategy to induce tumor regression?. Nature 445 (2007) 656-660
19. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC 22911). Lancet 366 (2005) 572-578
20. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
21. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response; results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol 53 (2002) 1097-1105
22. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
23. Tannock I.F., de Wit R., and Berry W.R. Tax 327 Investigators: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
24. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
25. D'Amico A.V., Moul J., Carroll P., et al. Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Ca Inst 95 (2003) 1376-1383
26. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439